BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Morgana Prá, Gabriela Kozuchovski Ferreira, Aline Haas de Mello, Rosiane de Bona Schraiber, Larissa Colonetti Cardoso, Luana da Rosa Souza, Naiana da Rosa, Jucélia Jeremias Fortunato, Gislaine Tezza Rezin. Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult ratsBiochemistry and Cell Biology 2016; 94(5): 451 doi: 10.1139/bcb-2016-0016
2
Brian DellaValle, Gitte S. Brix, Birgitte Brock, Michael Gejl, Jørgen Rungby, Agnete Larsen. Oral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain TraumaFrontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00450
3
Cosmin Sonea, Anca-Liliana Opris, Manuel F. Casanova, Ioan Opris, Marian Vladimir Constantinescu. The Physics of the Mind and Brain DisordersSpringer Series in Cognitive and Neural Systems 2017; 11: 469 doi: 10.1007/978-3-319-29674-6_21
4
Joana M. Gaspar, Filipa I. Baptista, M. Paula Macedo, António F. Ambrósio. Inside the Diabetic Brain: Role of Different Players Involved in Cognitive DeclineACS Chemical Neuroscience 2016; 7(2): 131 doi: 10.1021/acschemneuro.5b00240
5
Vladimer Darsalia, Thomas Klein, Thomas Nyström, Cesare Patrone. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potentialNeuropharmacology 2018; 136: 280 doi: 10.1016/j.neuropharm.2017.08.022
6
Ngom Issa Isaac, Decloquement Philippe, Armstrong Nicholas, Didier Raoult, Chabrière Eric. Metaproteomics of the human gut microbiota: Challenges and contributions to other OMICSClinical Mass Spectrometry 2019; 14: 18 doi: 10.1016/j.clinms.2019.06.001
7
Marcio C. Mancini, Maria Edna de Melo. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mgDiabetology & Metabolic Syndrome 2017; 9(1) doi: 10.1186/s13098-017-0242-0
8
R. U. Ostrovskaya, T. A. Antipova, S. V. Nikolaev, S. V. Kruglov, I. V. Ozerova, T. A. Gudasheva, S. B. Seredenin. Deficit of Neurotrophins in Experimental Diabetes – Correction with a Proline-Containing DipeptideNeuroscience and Behavioral Physiology 2019; 49(7): 809 doi: 10.1007/s11055-019-00806-z
9
Brian DellaValle, Gitte S. Brix, Birgitte Brock, Michael Gejl, Anne M. Landau, Arne Møller, Jørgen Rungby, Agnete Larsen. Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis RatsFrontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00433
10
Ivan N. Tyurenkov, Denis V. Kurkin, Dmitry A. Bakulin, Elena V. Volotova, Evgeny I. Morkovin, Mikhail A. Chafeev, Ruben N. Karapetian. Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00543
11
Andrei C. Sposito, Otávio Berwanger, Luiz Sérgio F. de Carvalho, José Francisco Kerr Saraiva. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome dataCardiovascular Diabetology 2018; 17(1) doi: 10.1186/s12933-018-0800-2
12
Violeta Arsenescu. Neuro-Immuno-Gastroenterology2016; : 157 doi: 10.1007/978-3-319-28609-9_8
13
Y. H. Lee-Barkey, B. Stratmann, D. Tschöpe. Inkretinbasierte DiabetesmedikamenteDer Diabetologe 2017; 13(7): 498 doi: 10.1007/s11428-017-0269-8
14
Qian Shi, Shuqian Liu, Vivian A Fonseca, Tina K Thethi, Lizheng Shi. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitusBMJ Open 2019; 9(7): e024954 doi: 10.1136/bmjopen-2018-024954
15
Grazyna Lietzau, Thomas Nyström, Claes-Göran Östenson, Vladimer Darsalia, Cesare Patrone. Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4Oncotarget 2016; 7(5): 5865 doi: 10.18632/oncotarget.6823
16
Shuyi Chen, Jie Sun, Gang Zhao, Ai Guo, Yanlin Chen, Rongxia Fu, Yanqiu Deng. Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic MiceNeurochemical Research 2017; 42(8): 2326 doi: 10.1007/s11064-017-2250-8
17
Ivan N. Tyurenkov, Alexander A. Ozerov, Denis V. Kurkin, Ekaterina O. Logvinova, Dmitry A. Bakulin, Elena V. Volotova, Dmitry D. Borodin. Structure and biological activity of endogenous and synthetic agonists of GPR119Russian Chemical Reviews 2018; 87(2): 151 doi: 10.1070/RCR4737
18
Laura Caberlotto, T.-Phuong Nguyen, Mario Lauria, Corrado Priami, Roberto Rimondini, Silvia Maioli, Angel Cedazo-Minguez, Giulia Sita, Fabiana Morroni, Mauro Corsi, Lucia Carboni. Cross-disease analysis of Alzheimer’s disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseasesScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-39828-5
19
Wenhui Yan, Miao Pang, Ye Yu, Xilan Gou, Peiru Si, Alina Zhawatibai, Yutong Zhang, Meng Zhang, Tingli Guo, Xinyao Yi, Lina Chen. The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosisLife Sciences 2019; 231: 116566 doi: 10.1016/j.lfs.2019.116566
20
Gang Zhang, Samuel Kim, Xiaohuan Gu, Shan Ping Yu, Ling Wei. DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic EffectsNeuroscience Bulletin 2020; 36(4): 407 doi: 10.1007/s12264-019-00446-w
21
Miaad Bader, Yazhou Li, David Tweedie, Nathan A. Shlobin, Adi Bernstein, Vardit Rubovitch, Luis B. Tovar-y-Romo, Richard D. DiMarchi, Barry J. Hoffer, Nigel H. Greig, Chaim G. Pick. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain InjuryFrontiers in Cell and Developmental Biology 2020; 7 doi: 10.3389/fcell.2019.00356
22
Emanuel Candeias, Inês Sebastião, Susana Cardoso, Cristina Carvalho, Maria Sancha Santos, Catarina Resende Oliveira, Paula I. Moreira, Ana I. Duarte. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic RatsMolecular Neurobiology 2017;  doi: 10.1007/s12035-017-0622-3
23
Jujun Xue, Cuiqing Wang, Chengli Pan, Haining Xing, Lijuan Xu, Xi Chen, Xuping Wang, Na Wang. Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCIExperimental and Therapeutic Medicine 2019;  doi: 10.3892/etm.2019.8339
24
WenXing Fan, Zhang Liang, Hua Xiao, QiuPing Yang. Therapeutic efficacy of liraglutide on diabetic nephropathy mice by inhibiting inflammatory factorsEuropean Journal of Inflammation 2018; 16: 205873921881928 doi: 10.1177/2058739218819283
25
Shuyi Chen, Mei Zhou, Jie Sun, Ai Guo, Roger Lakmal Fernando, Yanlin Chen, Peng Peng, Gang Zhao, Yanqiu Deng. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signalingNeuropharmacology 2019; 157: 107668 doi: 10.1016/j.neuropharm.2019.107668
26
Ahmed M. Kabel, Mohamed S. Omar, A. Alhadhrami, Salman S. Alharthi, Majed M. Alrobaian. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1Physiology & Behavior 2018; 188: 108 doi: 10.1016/j.physbeh.2018.01.028
27
Ana Knezovic, Jelena Osmanovic Barilar, Ana Babic, Robert Bagaric, Vladimir Farkas, Peter Riederer, Melita Salkovic-Petrisic. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s diseaseNeuropharmacology 2018; 135: 48 doi: 10.1016/j.neuropharm.2018.02.027
28
Rita Citraro, Michelangelo Iannone, Antonio Leo, Carmen De Caro, Valentina Nesci, Martina Tallarico, Karim Abdalla, Ernesto Palma, Franco Arturi, Giovambattista De Sarro, Andrew Constanti, Emilio Russo. Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesisBrain Research Bulletin 2019; 153: 133 doi: 10.1016/j.brainresbull.2019.08.001
29
Young-Kook Kim, Oh Yoen Kim, Juhyun Song. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic FunctionFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.01270
30
In-Kyung Jeong. Extrapancreatic Effect of Glucagon like Peptide-1The Korean Journal of Medicine 2015; 89(4): 404 doi: 10.3904/kjm.2015.89.4.404
31
Qiu-Ju Wang, Yi-Zhe Cui, Xiu-Ying Zhang, Jing Su. Effect of early weaning on the expression of excitatory amino acid transporter 1 in the jejunum and ileum of pigletsMolecular Medicine Reports 2017; 16(5): 6518 doi: 10.3892/mmr.2017.7421
32
Christian Hölscher. Brain insulin resistance: role in neurodegenerative disease and potential for targetingExpert Opinion on Investigational Drugs 2020; 29(4): 333 doi: 10.1080/13543784.2020.1738383
33
Ya-Kun Li, Dong-Xia Ma, Zhi-Min Wang, Xiao-Fan Hu, Shang-Lin Li, Hong-Zhe Tian, Meng-Jun Wang, Yan-Wen Shu, Jun Yang. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosisPharmacological Research 2018; 131: 102 doi: 10.1016/j.phrs.2018.03.004
34
Brhane Teklebrhan Assefa, Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Meles Tekie Gidey. The Bewildering Effect of AMPK Activators in Alzheimer’s Disease: Review of the Current EvidenceBioMed Research International 2020; 2020: 1 doi: 10.1155/2020/9895121
35
Syed Obaidur Rahman, Madhu Kaundal, Mohd Salman, Apeksha Shrivastava, Suhel Parvez, Bibhu Prasad Panda, Mymoona Akhter, Mohd Akhtar, Abul Kalam Najmi. Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's diseaseEuropean Journal of Pharmacology 2020; 889: 173522 doi: 10.1016/j.ejphar.2020.173522
36
J. A. Hutchinson, S. Burholt, I. W. Hamley. Peptide hormones and lipopeptides: from self-assembly to therapeutic applicationsJournal of Peptide Science 2017; 23(2): 82 doi: 10.1002/psc.2954
37
R. Loera‐Valencia, A. Cedazo‐Minguez, P.A. Kenigsberg, G. Page, A.I. Duarte, P. Giusti, M. Zusso, P. Robert, G. B. Frisoni, Annamaria Cattaneo, M. Zille, J. Boltze, N. Cartier, L. Buee, G. Johansson, B. Winblad. Current and emerging avenues for Alzheimer's disease drug targetsJournal of Internal Medicine 2019; 286(4): 398 doi: 10.1111/joim.12959
38
Christian Hölscher. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseasesInternational Review of Neurobiology 2020; 155: 65 doi: 10.1016/bs.irn.2020.01.007